Steven W. Pipe, MD, on Challenges in Gene Therapy Trials for Hemophilia

Video

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed common challenges with gene therapy clinical trials.

“As it stands right now, the safety and efficacy look quite encouraging. We believe that at least 1 platform for hemophilia A and 1 for hemophilia B will be submitted for regulatory review this year. I'm fully preparing our clinic to the fact that we may be doing commercial gene therapy either late in 2022 or early in 2023.”

Multiple companies are targeting hemophilia A and B indications for gene and cell therapy programs, with the goal of addressing Factor VIII deficiency in hemophilia A and Factor IX deficiency in hemophilia B.

CGTLive had the opportunity to speak with Steven W. Pipe, MD, a veteran of the field who has been involved with multiple gene therapy investigations. Pipe is director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital and is also a professor at University of Michigan Health.

Among Pipe’s investigations are the pivotal GENEr8-1 (NCT03370913) study of valoctocogene roxaparvovec (val-rox; Roctavian; BioMarin), the BLA filing for which was recently delayed by the FDA, as well as studies on etranacogene dezaparvovec by UniQure and another program by Bayer.1 A paper coauthored by Pipe was published in January 2022 exploring novel approaches to treating hemophilia A.2 In this clip, Pipe discussed the challenges of conducting gene therapy investigations in hemophilia.

REFERENCES
1. BioMarin delays hemophilia a therapy valoctocogene roxaparvovec filing as FDA calls for more data. News release. BioMarin. May 31, 2022. https://www.biospace.com/article/fda-needs-more-data-for-biomarin-s-hemophilia-a-therapy/
2. Pipe SW, Gonen-Yaacovi G, Segurado OG. Hemophilia A gene therapy: current and next-generation approaches. Expert Opin Biol. Published online January 6, 2022. doi:10.1080/14712598.2022.2002842
Related Videos
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
© 2024 MJH Life Sciences

All rights reserved.